LVCLF (Algorae Pharmaceuticals) 3-Year EBITDA Growth Rate : 37.00% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Algorae Pharmaceuticals 3-Year EBITDA Growth Rate?

Algorae Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 37.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 30.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Algorae Pharmaceuticals was 59.80% per year. The lowest was 4.40% per year. And the median was 22.05% per year.

Competitive Comparison of Algorae Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Algorae Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algorae Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Algorae Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Algorae Pharmaceuticals (OTCPK:LVCLF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Algorae Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Algorae Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (OTCPK:LVCLF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

LHI0:Germany 1AI:Australia

Address

525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000

Website

https://www.algoraepharma.com

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals Headlines

From GuruFocus

Living Cell Technologies Ltd at Vertical Events Gold Coast Investment Showcase Transcript

By GuruFocus Research • 02-14-2024